Type of PTM# of patients with tumors (% incidence)

 

Transplant

 
Reference Organ # pts # PatientsPTM Tumor site Skin (includesKS) HLM inclPTLD NCNLtumor
Kellerman [14] H 851 73(8.6%) - 6(8%) - 67(92%)
Favaloro [15] H 309 11(3.5%) - - 11(100%) -
Alam [16] H 6,271 440(7%) Skin 440(100%) - -
Caforio [17] H 488 51(10%) - NR 17(30%) 34(70%)
Crespo-Leiro [18] H 4,357 102(2.3%) Lu   - 102(100%)
Hamour [19] H 399 108(27%) - 52(48%) 40(37%) 16(15%)
Crespo-Leiro [20] H 3,393 639(19%) - 324(51%) 62(10%) 253(39%)
Jiang [21] H 1,703 160(9.4%) - NR 59(37%) 101(63%)
Hsu [22] H 291 17(5.8%) - 3(18%) 7(41%) 7(41%)
Molina [23] H 3,393 324(9.5%) Skin 324(100%) - -
Sanchez-Lazaro [24] H 597 109(18.3%) - 62(57%) 9(8%) 38(35%)
PTM, posttransplant malignancy, KS Kaposi’s sarcoma, HLM hematolymphoid malignancy, NCNL, non-cutaneous non-lymphomatous, H heart transplant, NR, not reported, Lu Lung
Table 2: Incidence of malignancy in HT recipients including single organ site or tumor types.